Natco Pharma transfers Lenalidomide ANDA to Arrow International
Hyderabad: Natco Pharma Limited has recently announced that the company has transferred the Lenalidomide Capsules ANDA (2.5mg, 5mg, l0mg, l5mg, 20mg and 25mg strengths) to Arrow International Limited as per an earlier agreement between the parties.
This transfer of the ANDA to Arrow does not materially change any of the terms of the agreement between the parties.
Arrow International Limited (an affiliate of Teva Pharmaceutical Industries Ltd) is the marketing partner of NATCO for this product in the US market.
The ANDA was approved by U.S. Food and Drug Administration (USFDA) in May 2021 with final approval in the 5mg, l0mg, l5mg, and 25mg strengths, and tentative approval in the 2.5mg and 20mg strengths.
Read also: Natco Pharma marketing partner gets USFDA nod for Carfilzomib Vials ANDA
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.